HIV Medication Therapy Management Services in Community Pharmacies
Overview
Pharmacy
Affiliations
Objectives: To present a rationale and a proposed structure to support pharmacist-delivered medication therapy management (MTM) for human immunodeficiency virus (HIV ) disease and to outline challenges to implementing and sustaining the service.
Data Sources: Professional literature.
Summary: Historically, the effect of pharmacy services for HIV-infected persons has been demonstrated in inpatient and clinic-based settings. Developing similar programs adapted for community pharmacists could be a model of care to improve patient adherence to antiretroviral therapy and retention in care. Initiation of antiretroviral therapy and regular monitoring of CD4+ cell count, HIV RNA viral load, adverse drug events, and adherence form the backbone of successful medical management of HIV infection. Support for these services can be provided to HIV-infected patients through pharmacist-managed HIV MTM programs in community pharmacy settings in collaboration with primary providers and other health care professionals.
Conclusion: Community pharmacists can help meet the growing need for HIV care through provision of MTM services. Although resources have been developed, including the general MTM framework, challenges of adequate training, education, and support of community pharmacists need to be addressed in order for HIV MTM to be a successful model.
Oseni Y, Erhun W BMC Prim Care. 2024; 25(1):315.
PMID: 39187789 PMC: 11346140. DOI: 10.1186/s12875-024-02568-1.
Building health plan-pharmacist provider partnerships to optimize medication outcomes.
Pestka D, Sorensen T, Westberg S J Manag Care Spec Pharm. 2023; 29(12):1284-1289.
PMID: 38058143 PMC: 10701258. DOI: 10.18553/jmcp.2023.29.12.1284.
Kang J, Farkhad B, Chan M, Michels A, Albarracin D, Wang S PLoS One. 2022; 17(7):e0270404.
PMID: 35895722 PMC: 9328561. DOI: 10.1371/journal.pone.0270404.
Tarfa A, Pecanac K, Shiyanbola O Pharmacy (Basel). 2021; 9(4).
PMID: 34842829 PMC: 8628938. DOI: 10.3390/pharmacy9040178.
Molas M, Knobel H, Ferrandez O, de Antonio Cusco M, Carballo Martinez N, Rodriguez Caba C Rev Esp Quimioter. 2021; 35(1):71-75.
PMID: 34823348 PMC: 8790649. DOI: 10.37201/req/055.2021.